Company Names, identifiers, and filing context for this profile. 1 identity field
Company location
Bedminster, NJ
SEC filing record 1 source field available
Fiscal year end
31 December
Intra-Cellular Therapies, Inc. has filed 1,007 SEC EDGAR filings since 08 Feb 2013

SEC filing history

Showing 976-1,000 of 1,000 matching filings.

Per page
25
Current page
40
D File 021-202688

D filing

Filing date
11 Sep 2013
Reporting date
Not listed
SEC evidence
Open document Open filing
Next action
Verify source filing
3

FORM 3 - ALAFI CAPITAL COMPANY, LLC

Filing date
09 Sep 2013
Reporting date
29 Aug 2013
SEC evidence
Open document Open filing
Next action
Verify source filing
3

PRIMARY DOCUMENT

Filing date
09 Sep 2013
Reporting date
29 Aug 2013
SEC evidence
Open document Open filing
Next action
Verify source filing
SC 13G File 005-87380

SC 13G filing

Filing date
09 Sep 2013
Reporting date
Not listed
SEC evidence
Open document Open filing
Next action
Verify source filing
3

FORM 3 - MOSHE ALAFI

Filing date
09 Sep 2013
Reporting date
29 Aug 2013
SEC evidence
Open document Open filing
Next action
Verify source filing
3

FORM 3 - CHRISTOPHER ALAFI, PH.D.

Filing date
09 Sep 2013
Reporting date
29 Aug 2013
SEC evidence
Open document Open filing
Next action
Verify source filing
SC 13G File 005-87380

SC 13G

Filing date
09 Sep 2013
Reporting date
Not listed
SEC evidence
Open document Open filing
Next action
Verify source filing
3

FORM 3 - SIR MICHAEL RAWLINS, M.D., FRCP, FMEDSCI

Filing date
09 Sep 2013
Reporting date
29 Aug 2013
SEC evidence
Open document Open filing
Next action
Verify source filing
3

FORM 3 - RICHARD LERNER, M.D.

Filing date
09 Sep 2013
Reporting date
29 Aug 2013
SEC evidence
Open document Open filing
Next action
Verify source filing
3

FORM 3 - KIMBERLY E. VANOVER, PH.D.

Filing date
09 Sep 2013
Reporting date
29 Aug 2013
SEC evidence
Open document Open filing
Next action
Verify source filing
3

FORM 3 - LAWRENCE P. WENNOGLE, PH.D.

Filing date
09 Sep 2013
Reporting date
29 Aug 2013
SEC evidence
Open document Open filing
Next action
Verify source filing
3

FORM 3 - ALLEN A. FIENBERG, PH.D.

Filing date
09 Sep 2013
Reporting date
29 Aug 2013
SEC evidence
Open document Open filing
Next action
Verify source filing
3

FORM 3 - LAWRENCE J. HINELINE

Filing date
09 Sep 2013
Reporting date
29 Aug 2013
SEC evidence
Open document Open filing
Next action
Verify source filing
3

FORM 3 - SHARON MATES, PH.D.

Filing date
09 Sep 2013
Reporting date
29 Aug 2013
SEC evidence
Open document Open filing
Next action
Verify source filing
SC 13D File 005-87380

SC 13D

Filing date
09 Sep 2013
Reporting date
Not listed
SEC evidence
Open document Open filing
Next action
Verify source filing
SC 13D File 005-87380

SC 13D

Filing date
09 Sep 2013
Reporting date
Not listed
SEC evidence
Open document Open filing
Next action
Verify source filing
SC 13D File 005-87380

SC 13D

Filing date
09 Sep 2013
Reporting date
Not listed
SEC evidence
Open document Open filing
Next action
Verify source filing
8-K File 000-54896

FORM 8-K

Filing date
05 Sep 2013
Reporting date
29 Aug 2013
SEC evidence
Open document Open filing
Next action
Verify source filing
SC 14F1 File 005-87380

SC 14F1

Filing date
29 Aug 2013
Reporting date
Not listed
SEC evidence
Open document Open filing
Next action
Verify source filing
8-K File 000-54896

FORM 8-K

Filing date
29 Aug 2013
Reporting date
23 Aug 2013
SEC evidence
Open document Open filing
Next action
Verify source filing
10-Q File 000-54896

QUARTERLY REPORT

Filing date
14 Aug 2013
Reporting date
30 Jun 2013
Next action
Verify source filing
10-K File 000-54896

ANNUAL REPORT

Filing date
16 Jul 2013
Reporting date
31 Mar 2013
Next action
Verify source filing
NT 10-K File 000-54896

NOTIFICATION OF LATE FILING

Filing date
02 Jul 2013
Reporting date
31 Mar 2013
SEC evidence
Open document Open filing
Next action
Verify source filing
SC 13G File 005-87380

SCHEDULE 13G

Filing date
09 Apr 2013
Reporting date
Not listed
SEC evidence
Open document Open filing
Next action
Verify source filing
We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Manage preferences to update or revoke optional consent for future visits. For more information, see our Privacy Policy .